상세정보
Export to Refworks부가기능
Engineering T Cells with Diverse Mechanisms for Improved Tumor Recognition Precision
상세 프로파일
| 자료유형 | 학위논문 |
|---|---|
| 서명/저자사항 | Engineering T Cells with Diverse Mechanisms for Improved Tumor Recognition Precision. |
| 개인저자 | Williams, Jasper Zee. |
| 단체저자명 | University of California, San Francisco. Pharmaceutical Sciences and Pharmacogenomics. |
| 발행사항 | [S.l.]: University of California, San Francisco., 2019. |
| 발행사항 | Ann Arbor: ProQuest Dissertations & Theses, 2019. |
| 형태사항 | 198 p. |
| 기본자료 저록 | Dissertations Abstracts International 81-04B. Dissertation Abstract International |
| ISBN | 9781085651547 |
| 학위논문주기 | Thesis (Ph.D.)--University of California, San Francisco, 2019. |
| 일반주기 |
Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
Advisor: Szoka, Francis C. |
| 이용제한사항 | This item must not be sold to any third party vendors.This item must not be added to any third party search indexes. |
| 요약 | Engineered T cells are proven cancer therapeutics capable of executing potent antigen-dependent cell killing, and have gained FDA-approval after unprecedented results against certain blood cancers. However, successful treatment of solid tumors has been limited in large part by the lack of targetable antigens that are not also expressed in healthy tissues, as exhibited by ON-target OFF-tumor cross-reactive fatal toxicities seen in various human trials. An advantage of cell-based therapies is that cells can "compute" and execute more sophisticated programs than traditional drugs. Combinatorial antigen recognition has recently been introduced to overcome ON-target OFF-tumor toxicity limitations associated with traditional single antigen-targeted T cell therapies. This dissertation focuses on developing T cell engineering and biomaterials toolkits to expand the capabilities of combinatorial antigen-sensing T cell therapies. First presented is a set of approaches that use synNotch receptors and other synthetic receptors to program T cells with a diverse array of novel combinatorial antigen sensing circuits. It is shown that these Boolean logic-gated synNotch T cells can be engineered to sense both extracellular and intracellular antigens, target up to 3 antigens, integrate positive and negative regulation, and incorporate bispecific receptors. These abilities could enable engineering therapeutic T cells with the ability to target truly tumor-specific antigen combination signatures identified via bioinformatic analysis of antigen expression in cancer versus healthy cells. Also presented is a system to engineer T cells to recognize an orthogonal cue on biocompatible particles and incorporate this detection into combinatorial antigen-sensing circuits to specifically kill antigen positive tumor cells only in the presence of the particles. Using particles to control therapeutic cell activity in the body has the potential to enhance safety by enabling dynamic, local user-control of engineered cells during treatment. Together, the technologies presented here facilitate the development of engineered T cells to safely target a broader range of cancers. The toolkits developed here can be used to engineer T cell therapies to target cancer cells with significantly improved precision by taking advantage of our modern capabilities in cancer informatics, cell engineering, and biomaterials. |
| 일반주제명 | Pharmaceutical sciences. Physiology. Medicine. Histology. Epidemiology. Immunology. Public health. Oncology. Pathology. Health sciences. |
| 언어 | 영어 |
| 바로가기 | 
: 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |
